Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. The company has a presence in markets, such as the United States, the United Kingdom, and Germany, as well as other primary markets, such as India, Russia, Venezuela, Romania, South Africa, and certain countries of the former Soviet Union. Segments The company’s segments include Global Generics; Pharmaceutical Services and Active Ingredients (PSAI); and Proprietary Products. Global Generics This segment consists of the company’s business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the company’s biologics business. India In India, the company’s major therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. The company is also increasing its presence in the niche areas of dermatology, urology, and nephrology. As of March 31, 2016, the company had a total of 296 branded products in India. IMS Health Inc. is a provider of market research to the Indian pharmaceutical industry. Sales, Marketing and Distribution Network: The company generates demand for its products through its 5,662 sales representatives (which include representatives engaged by the company on a contract basis through a service provider) and front line managers, who frequently visit doctors to detail its related product portfolio. The company sells its products primarily through clearing and forwarding agents to approximately 3,000 wholesalers who decide which brands to buy based on demand. The wholesalers pay for the company’s products in an agreed credit period and in turn sell these products to retailers. The company’s clearing and forwarding agents are responsible for transporting its products to the wholesalers. Competition: The company’s principal competitors in the Indian market include Cipla Limited; GlaxoSmithKline Pharmaceuticals Limited; Cadila Healthcare Limited; Sun Pharmaceutical Industries Limited; Piramal Enterprises Ltd; Alkem Limited; Mankind Pharma Limited; Pfizer Limited; Abbott India; Lupin Limited; Aristo Pharma Limited; Intas Pharma; Sanofi India Limited; and Emcure Pharmaceuticals Limited. Russia and other Countries of the former Soviet Union Russia: The company’s major four brands include Nise, Omez, Ketorol, and Cetrine. The company’s strategy in Russia is to focus on the gastro-intestinal, pain management, anti-infectives, respiratory, oncology, and cardiovascular therapeutic areas. The company’s focus is on building major brands in these therapeutic areas in prescription, OTC and hospital sales. Other Countries of the former Soviet Union: The company operates in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus, Uzbekistan and Romania. Sales, Marketing and Distribution Network: The company’s marketing and promotion efforts in its Russian prescription division is driven by a team of 268 medical representatives and 38 managers to detail its products to doctors in 77 cities in Russia. The company’s Russian OTC division has 216 medical representatives and 31 managers, and is focused on establishing a network of relationships with key pharmacy chains and individual pharmacies. The company’s Russian hospital division has 38 hospital specialists and 17 key account managers, and is focused on expanding its presence in hospitals and institutes. Competition: The company’s principal competitors in the Russian market include Berlin Chemi AG; Gedeon Richter Limited; Krka d.d.; Teva Pharmaceutical Industries Ltd.; Lek-Sandoz Pharmaceuticals (an affiliate of Novartis Pharma A.G.); Ranbaxy Laboratories Limited; Nycomed International Management GmbH; and Zentiva N.V. (an affiliate of Sanofi-Aventis S.A.). North America (the United States and Canada) In the United States, the company sells generic drugs that are the chemical and therapeutic equivalents of ref
doctor reddy's lab-adr (RDY:New York)
8-2-337, Road No. 3
Phone: 91 40 4900 2900
Fax: 91 40 4900 2999www.drreddys.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for RDY.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.